|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||346.15 - 346.15|
|52-week range||290.50 - 432.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||19.96|
|Forward dividend & yield||10.25 (3.00%)|
|Ex-dividend date||16 Mar 2023|
|1y target est||N/A|
Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Swiss drugmaker Roche Holding AG plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will shut the factory by 2029, according to e-mailed letters to workers seen by Reuters on Wednesday. In a statement, Roche confirmed the divestiture plan for the site, which makes monoclonal antibodies from genetically modified living cells, but did it not address the potential closing of the plant or its timeline. It also plans to focus on drugs targeting smaller patient populations moving forward and to draw on a range of biotechnology methods beyond monoclonal antibodies, it said, adding there would be no impact to operations or employees at this time.
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in the arms and legs. Rain said that milademetan, an inhibitor of the MDM2-p53 complex that reactivates p53, a known tumor inhibitor, taken orally, did not meet its primary endpoint of efficacy in a phase 3 trial to treat patients with dedifferentiated (DD) liposarcoma (LPS). Based on the disappointing results, Rain said it does not plan to pursue further development of the therapy to treat DD LPS.
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
By Vlad Schepkov
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.
(Reuters) -Switzerland's Roche said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and tests, less steep than analysts had expected thanks to strong revenue growth from a new eye drug. Group revenue fell to 15.3 billion Swiss francs ($17.2 billion), the company reported on Wednesday, beating a market view of 14.8 billion francs on a strong launch of anti-blindness treatment Vabysmo and better-than-expected sales of COVID antibody treatment Ronapreve. The company, which does not report earnings for its first quarter, reiterated that pandemic-related sales - mainly lab testing, Ronapreve and repurposed arthritis drug Actemra - would drop by 5 billion francs this year.
Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated DLBCL.
Roche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of Tecentriq and Avastin reduces the risk of cancer relapsing in people with certain types of adjuvant liver cancer in a phase III study.
Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.
Health investment and innovation has been on a roller coaster as a result of the pandemic. But the momentum needs to continue, according to Michael Milken.
FDA accepts Pfizer's (PFE) sNDAs seeking approval of Braftovi + Mektovi for BRAF V600E-mutant non-small cell lung cancer.
To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.
Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys are included in this Analyst Blog.
Swiss pharmaceutical company Roche (OTC: RHHBY) took a hit from a decline in sales of COVID-19 diagnostic and treatment products in 2022, with group sales inching up 2% at constant exchange rates (CER) to 63.28 billion Swiss francs ($68.34 billion). The company's pharmaceutical and diagnostic divisions were both affected, and net income came in at 13.5 billion francs ($14.6 billion), a decline of 6% compared to 2021 under international financial reporting standards (IFRS). The company expects "the sharp decline in sales of COVID-19 products" to continue through 2023, leading sales to decrease "in the low single digit range," although it also expects its sales of other products to show strong growth.